SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company today announced the detailed results of two advanced phase studies that show that people suffering from obesity from a therapy with injectable incretines at the maximum dose maintained long-term weight loss after the passage to orforglipron or a lower dose of tirzepatide. The results of the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN studies were presented at the 3rd European Congress on Obesity (ECO) in Istanbul and published respectively on The Lancet and Nature Medicine.“The SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN trials shift the focus from initial weight loss to durability and long-term cardiometabolic benefits. An important change of perspective, which reflects the clinical complexity of obesity: a chronic pathology that requires continuous treatment over time – says Paolo Sbraccia Professor of Internal Medicine, University of Rome “Tor Vergata” and Director of the UOC of Internal Medicine and the Center for Obesity Care, Policlinico Tor Vergata -. The data is clear: both with tirzepatide and with orforglipron weight loss is maintained without significant recovery. ATTAIN-MAINTAIN, in particular, supports a continuity of results in terms of effectiveness in the injective passage to oral and, while without implying a direct equivalence between the two formulations, the hypothesis of a therapeutic continuity”. In the SURMOUNT-MAINTAIN study, both MTD tirzepatide and 5 mg have reached the primary endpoint and all key secondary endpoints, demonstrating the maintenance of weight loss after 60 weeks of initial treatment with MTD tirzepatide. The primary endpoint was to show that the continuation of treatment with tirzepatide, at a reduced dose of 5 mg and MTD, was higher than the placebo in terms of percentage change of body weight per week 112. On week 112, patients who continued treatment with MTD tirzepatide maintained all previous weight loss, while reducing the dose to 5 mg allowed to maintain on average all weight loss, with an average 5.6 kg scaling.The ATTAIN-MAINTAIN study has shown that the transition to orforglipron also favors the maintenance of the long-term weight, reaching the primary endpoint and secondary endpoint The primary endpoint was to demonstrate that orforglipron was higher than the placebo in the maintenance percentage of body weight reduction among participants in the SURMOUNT-5 study who had previously reached a body weight plateau. At week 52, participants who have passed from MTD semaglutide to orforglipron have maintained all the weight loss previously achieved except 0.9 kg, while those who have passed from tirzepatide MTD to orforglipron have maintained all weight loss with an average deviation of 5.0 kg. We are encouraged by the results of SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN, which have shown that both tirzepathy and orforglipron, an oral GLP-1 to be taken once a day, have ensured a lasting maintenance of weight loss. Lilly is committed to providing people with different therapeutic options in their weight loss path.” In both studies, orforglipron and tirzepatide have demonstrated consistent safety profiles with previous Phase 3 studies. In the study ATTAIN-MAINTAIN, the most common adverse events with orforglipron regarding the placebo were nausea (18.8% vs. 4.1%), constipation(13.1% vs. 4.1%), vomiting (8.3% vs. 3.4%) or diarrhea (7.4% vs. 7.5%). Treatment interruption rates due to adverse events for randomized patients at placebo or orfroglipron were 4.8% (orforglipron from semaglutide), 7.6% (semaglutide placebo), 7.2% (orforglipron from tirzepatide) and 6.3% (Tirzepatide placebo). In the SURMOUNT-MAINTAIN study, the most common adverse events during the maintenance period with tirzepatide MTD and tirzepatide 5 mg compared to the placebo were diarrhea (7.2% and 4.9% versus 1.1%), vomiting (6.5% and 0.7% versus 0%) and nausea (5.8% and 4.2% versus 2.2%). Treatment interruption rates due to adverse events during the maintenance period with tirzepatide MTD, tirzepatide 5 mg and placebo were 0%, 0.7% and 0% respectively.
– Press Office photos Eli Lilly –
(ITALPRESS).
